Torrent Pharmaceuticals will report its March quarter earnings on Tuesday. A CNBC-TV18 poll is expecting revenue to be flat on a year-on-year basis. Margins to probably improve around a 100 basis points odd and a profit to decline.
In terms of the domestic business, last quarter it was up around 6-7 percent odd so this quarter analysts are expecting to grow up to around 10 percent on a year-on-year basis.
Chronic therapies are probably expected to improve in terms of sales.
US business is expected to continue being subdued because of the regulatory issues that the company has been facing, lack of approvals due to COVID-19 and hence the street is anticipating a decline of around 2-3 percent odd.CNBC-TV18’s Ekta Batra has more detail. Watch this video for more.